Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Glioblastoma 6Fallopian Tube Neoplasms 6Breast Neoplasms 6Gliosarcoma 5Carcinoma, Non-Small-Cell Lung 5Prostatic Neoplasms 4Ovarian Neoplasms 4Melanoma 4Carcinoma, Renal Cell 4Brain Neoplasms 4Solitary Fibrous Tumor, Pleural 3Mesothelioma, Malignant 3Carcinoma, Hepatocellular 3Breast Neoplasms, Male 3Triple Negative Breast Neoplasms 2Sarcoma, Alveolar Soft Part 2Rectal Neoplasms 2Oligodendroglioma 2Leukemia, Myeloid, Acute 2Colonic Neoplasms 2Carcinoma, Ovarian Epithelial 2Astrocytoma 2Waldenstrom Macroglobulinemia 1Uveal Melanoma 1Uterine Cervical Neoplasms 1Tongue Neoplasms 1Thyroid cancer, Hurthle cell 1Thyroid Cancer, Papillary 1Squamous Cell Carcinoma of Head and Neck 1Spinal Cord Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 6Iodine-131 3Fluorodeoxyglucose F18 32-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 3Trastuzumab 2Sorafenib 2Radiotherapy 2trametinib 1tipifarnib 1tanespimycin 1sargramostim 1romidepsin 1omipalisib 1gallium Ga 68 dotatate 1cediranib 1cabozantinib 1aldesleukin 1aflibercept 1Vorinostat 1Triiodothyronine 1Thyrotropin Alfa 1Tamoxifen 1Sunitinib 1Specimen Handling 1Rosiglitazone 1Ritonavir 1Radiofrequency Ablation 1Pharmacogenomic Testing 1Nivolumab 1Lenalidomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Thyroid Cancer, Papillary × cediranib × Clear all
NCT01208051 2021-07-15

Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
127 enrolled 18 charts
EndocrineHead & Neck

Thyroid cancer, Hurthle cell, Thyroid Cancer, Papillary, Adenocarcinoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡